News

Synergy filed a voluntary petition for reorganization under Chapter 11 of the U.S. Code (the Bankruptcy Code) with the US Bankruptcy Court for the Southern District of New

With this approval, Xolair is the first and only biologic to offer the option of self-administration for SAA and CSU. Xolair, which targets immunoglobulin E (IgE), is the

The partners will combine the Morphomer platform technology of the Switzerland-based AC Immune with the clinical development expertise and commercial capabilities of Lilly in central nervous system disorders

The deal will allow AMAG to acquire global rights of ciraparantag, a next generation anticoagulant reversal agent, from Perosphere. As per terms of the deal, Perosphere equityholders will

Under the terms of the agreement, X-Chem will utilize its industry-leading DNA-encoded library (DEX) screening platform and proprietary informatics tools to search for novel hits for Almirall targets.

Targeting this biochemical pathway may help develop new therapies for alleviating the symptoms of anxiety disorders. The lab of Prof. Mike Fainzilber in the Institute’s Biomolecular Sciences Department

The phase 3 trial, called ECLIPSE, enrolled 1048 patients to evaluate the efficacy and safety of Tremfya in comparison to Cosentyx. While Tremfya is an interleukin (IL)-23-targeted biologic

The joint team is focused on the discovery of efficacious inhibitors of PknB, which is essential for the growth of Mycobacterium tuberculosis (TB). Schrödinger’s computational platform has led

Zilucoplan, which is a synthetic, macrocyclic peptide, achieved clinically meaningful and statistically significant reductions across the primary and key secondary endpoints for its two dose groups in comparison